#1 Clinical Trials Search in Europe

Topotecan

Topotecan is a chemotherapy drug that has been the subject of numerous clinical trials investigating its effectiveness in treating various types of cancer and other medical conditions. This article summarizes key findings from recent clinical trials using topotecan, highlighting its potential benefits, side effects, and applications across different diseases.

Table of Contents

What is Topotecan?

Topotecan is a chemotherapy drug used to treat various types of cancer. It’s also known by its brand names Hycamtin[1], Hycamptamine[9], and TOPO[9]. Topotecan belongs to a class of drugs called topoisomerase inhibitors, which work by interfering with the growth and spread of cancer cells in your body[1].

How Topotecan Works

Topotecan works by stopping cancer cells from dividing and growing. It does this by targeting an enzyme called topoisomerase I, which is essential for DNA replication in cancer cells. By inhibiting this enzyme, topotecan causes the cancer cells to stop growing or die[1].

Conditions Treated with Topotecan

Topotecan is used to treat several types of cancer, including:

  • Leukemia: Including chronic myelogenous leukemia and recurrent acute leukemia[8]
  • Lung Cancer: Particularly non-small cell lung cancer[4][5]
  • Ovarian Cancer: Especially advanced stages (III and IV)[9]
  • Cervical Cancer: Including locally advanced cervical cancer[10]
  • Ewing Sarcoma and Neuroblastoma: Particularly in relapsed or refractory cases[6][7]
  • Solid Tumors: Various types of solid tumors in adults[2]

How Topotecan is Administered

Topotecan is typically administered intravenously (IV), which means it’s given directly into your bloodstream through a vein. The dosage and schedule can vary depending on the specific condition being treated and other factors. Some common administration methods include:

  • 30-minute infusions on specific days of a treatment cycle[2]
  • Continuous infusion over several days[4]
  • Weekly administration in combination with other drugs[10]

Your healthcare team will determine the best administration method for your specific case.

Topotecan in Combination Therapies

Topotecan is often used in combination with other cancer treatments to enhance its effectiveness. Some common combinations include:

  • Topotecan with paclitaxel and cisplatin for ovarian cancer[9]
  • Topotecan with cyclophosphamide for Ewing sarcoma and neuroblastoma[6]
  • Topotecan with radiation therapy for cervical cancer[10]
  • Topotecan with cabozantinib for relapsed Ewing sarcoma or osteosarcoma[7]

These combinations are designed to target cancer cells in multiple ways, potentially improving treatment outcomes.

Potential Side Effects

Like all chemotherapy drugs, topotecan can cause side effects. Some common side effects may include:

  • Decreased blood cell counts (white blood cells, red blood cells, and platelets)[8]
  • Fatigue
  • Nausea and vomiting
  • Hair loss
  • Diarrhea

Your healthcare team will monitor you closely for these and other side effects. They may prescribe additional medications or adjust your treatment plan to help manage side effects.

Ongoing Research and Clinical Trials

Researchers continue to study topotecan to find new ways to use it effectively and safely. Some areas of ongoing research include:

  • Determining the best dosages and schedules for different types of cancer[6][7]
  • Exploring new drug combinations to improve treatment outcomes[7]
  • Investigating topotecan’s effectiveness in treating additional types of cancer
  • Studying ways to reduce side effects and improve quality of life for patients receiving topotecan

Clinical trials are an important part of this research. If you’re interested in participating in a clinical trial involving topotecan, talk to your doctor about potential opportunities.

Condition Trial Type Key Findings/Objectives
Ovarian Cancer Phase 3 Randomized Comparing CAELYX vs. topotecan in recurrent epithelial ovarian carcinoma after first-line platinum-based chemotherapy failure
Small Cell Lung Cancer Observational Registry Collecting real-world data on treatment and outcomes of SCLC patients receiving HYCAMTIN (topotecan) and other drugs
COVID-19 Phase 1 Dose-escalation Evaluating safety and potential anti-inflammatory effects of low-dose topotecan in moderate-severe COVID-19 patients
Neoplastic Meningitis Phase 1 Pharmacokinetic Determining optimal intrathecal topotecan dosing for children with neoplastic meningitis
Pediatric Solid Tumors Phase 2 Investigating the combination of topotecan and temozolomide in refractory and relapsed pediatric solid tumors
Myeloproliferative Disorders Phase 2 Randomized Comparing topotecan/carboplatin with or without veliparib in advanced myeloproliferative disorders and leukemias
Proliferative Vitreoretinopathy Randomized Controlled Trial Evaluating safety and efficacy of intravitreal topotecan for treating proliferative vitreoretinopathy in retinal detachment cases

FAQ

  • What types of cancer is topotecan being studied for? Topotecan is being studied for several types of cancer, including ovarian cancer, small cell lung cancer, neuroblastoma, and various pediatric solid tumors. It's also being investigated for use in acute myeloid leukemia and myeloproliferative disorders.
  • How is topotecan typically administered? Topotecan is usually administered intravenously (IV) over 30 minutes to 24 hours, depending on the specific protocol. In some trials, it's given daily for 3-5 consecutive days in cycles, while others use weekly administration schedules.
  • What are some common side effects of topotecan? Common side effects of topotecan include hematological toxicities such as neutropenia (low white blood cell count), anemia, and thrombocytopenia (low platelet count). Other side effects may include fatigue, nausea, and diarrhea.
  • Is topotecan being studied in combination with other drugs? Yes, many clinical trials are investigating topotecan in combination with other drugs. For example, it's being studied with carboplatin for ovarian cancer, with temozolomide for pediatric solid tumors, and with veliparib for myeloproliferative disorders.
  • Are there any non-cancer conditions being studied with topotecan? Yes, topotecan is being investigated for use in proliferative vitreoretinopathy, an eye condition that can occur after retinal detachment surgery. It's also being studied at low doses for potential use in COVID-19 patients to reduce inflammation.

Ongoing Clinical Trials on Topotecan

  • Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Denmark Finland France +9

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Finland France Germany Greece Hungary +7

  • Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +4

  • Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +4

  • Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7

  • Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal

Glossary

  • Topotecan: A chemotherapy drug that works as a topoisomerase I inhibitor, used to treat various types of cancer.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Neutropenia: A condition characterized by an abnormally low number of neutrophils, a type of white blood cell important for fighting infections.
  • Thrombocytopenia: A condition where there is a lower than normal number of platelets in the blood, which can lead to increased bleeding risk.
  • Proliferative Vitreoretinopathy (PVR): A complication that can occur after retinal detachment, characterized by the growth of scar tissue on the retina.
  • Rhegmatogenous Retinal Detachment: A type of retinal detachment caused by a tear or break in the retina, allowing fluid to accumulate underneath it.
  • Neoplastic Meningitis: A condition where cancer cells spread to the membranes surrounding the brain and spinal cord.
  • Myeloproliferative Disorders: A group of blood cancers characterized by the overproduction of certain types of blood cells in the bone marrow.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Dose-Limiting Toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a reduction in dosage.

References

  1. https://clinicaltrials.gov/study/NCT00002705
  2. https://clinicaltrials.gov/study/NCT00002587
  3. https://clinicaltrials.gov/study/NCT00888810
  4. https://clinicaltrials.gov/study/NCT00002537
  5. https://clinicaltrials.gov/study/NCT00065182
  6. https://clinicaltrials.gov/study/NCT01492673
  7. https://clinicaltrials.gov/study/NCT04661852
  8. https://clinicaltrials.gov/study/NCT00002693
  9. https://clinicaltrials.gov/study/NCT00002913
  10. https://clinicaltrials.gov/study/NCT00054444